GSK strikes deal to buy US vaccine firm Affinivax
dailymail.co.uk
news
2022-05-31 09:26:42

Published: 05:26 EDT, 31 May 2022 | Updated: 05:26 EDT, 31 May 2022 GlaxoSmithKline (GSK) has agreed to buy US vaccine technology firm Affinivax in deal worth up to 3.3 billion dollars (£2.6 billion). It comes as the UK pharmaceutical business seeks to bolster its vaccine operation as part of a shake-up of its portfolio, including the spin-off of its consumer health business. GSK told shareholders on Tuesday that it will buy the Boston-based biotech company for an upfront payment of 2.1 billion dollars (£1.
